[LETTER FROM PREDECESSOR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 100 F Street, NE Dear Ladies and Gentlemen: Brea,lifornia January 7, 2010 LETTER FROM MSWFT v170753_ex16-1.htm 2 EX-16.1]
[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]
[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]
[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]
[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]
[Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million in incremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational initiatives for]
[Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million in incremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational initiatives for]
[Biostar Pharmaceuticals, to Launch Xin Aoxing Oleanolic Acidpsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million inremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational]
[Biostar Pharmaceuticals, to Launch Xin Aoxing Oleanolic Acidpsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million inremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational]
[1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Number of 7 Sole Voting Power Shares Owned]
